Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. A placebo-controlled trial.
Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. A placebo-controlled trial.
复制标题
DOI：
10.1001/archfami.2.4.417
复制
发表时间：
1993-04-01
期刊：
影响因子：
--
通讯作者：
Costello, J
中科院分区：
文献类型：
--
作者：
Foulds, J;Stapleton, J;Costello, J
目的：为了评估透皮尼古丁贴片结合低强度支持是否可以帮助综合医院的门诊患者戒烟，设计：随机、双盲、安慰剂对照试验，随访12周。某综合医院门诊248例患者，每天吸烟10支以上（大多数人正在接受与吸烟有关的疾病的治疗），由医院的临床医生转介。戒烟建议及每日使用尼古丁贴片（16小时内给予15 mg）或安慰剂，在第1、3、6和12周进行随访，第1周继续吸烟者的剂量加倍。主要结果指标：通过测量第3、6和12周的呼吸空气中一氧化碳浓度，验证了从第3周到第12周的持续戒烟。二十九（23.4%）被分配到尼古丁组的124名受试者在第3周和第6周都被证实戒烟，而接受安慰剂的124名受试者中有16名（12.9%）（P = 0.008）。在第12周，尼古丁组中的22名受试者（17.7%）被验证为在所有三个点都戒烟，安慰剂组中的15名受试者（12.1%）也是如此（P = 0.058）。结论：经皮尼古丁贴片结合低强度支持可有效帮助综合医院的门诊患者戒烟，但6周后不能防止复发。
OBJECTIVE: To assess whether transdermal nicotine patches combined with low-intensity support can help outpatients in a general hospital stop smoking.DESIGN: Randomized, double-blind, placebo-controlled trial with 12 weeks of follow-up.SETTING: Department of Thoracic Medicine in an inner-city public general hospital, London, England.SUBJECTS: Two hundred forty-eight outpatients in a general hospital, who smoked at least 10 cigarettes per day (the majority were being treated for smoking-related diseases), referred by clinicians at the hospital.INTERVENTION: Brief advice to stop smoking and daily application of transdermal nicotine patches (delivering 15 mg over 16 hours) or placebo, with follow-up appointments at 1, 3, 6, and 12 weeks, with a doubling of the dosage for continuing smokers at week 1.MAIN OUTCOME MEASURE: Sustained abstinence from tobacco from week 3 to week 12 validated with measurement of expired-air carbon monoxide concentration at weeks 3, 6, and 12.RESULTS: Twenty-nine (23.4%) of 124 subjects assigned to the nicotine group were validated as having abstained from smoking at both weeks 3 and 6, compared with 16 (12.9%) of 124 subjects receiving placebo (P = .008). At week 12, 22 (17.7%) of the subjects in the nicotine group were validated as having abstained at all three points as were 15 (12.1%) of the subjects in the placebo group (P = .058).CONCLUSION: Transdermal nicotine patches combined with low-intensity support are effective in helping outpatients in a general hospital stop smoking but do not prevent relapse after 6 weeks.